Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: Reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan

摘要: To determine the reliability and validity of a patient outcome questionnaire for chronic heart failure, randomized, double-blind, placebo-controlled, 3-month trial pimobendan, an investigational medication with inotropic vasodilator activities, was performed. Evaluated were 198 ambulatory patients primarily New York Heart Association (NYHA) class III failure from 20 referral centers. Baseline therapy included digoxin, diuretics and, in 80%, converting enzyme inhibitor. Oral pimobendan at 2.5 (n = 49), 5.0 51), or 10 49) mg daily matching placebo administered. The Minnesota Living Failure (LIhFE) primary measure, along exercise test. Interitem correlations identified subgroups questions representing physical emotional dimensions. Repeated baseline scores highly correlated (r 0.93), as 0.89) 0.88) dimension scores. Placebo did not have significant effect median (25th, 75th percentile) changes 1 (-3, 5), (-2, 3), 0 (-1, 2), respectively (all p values greater than 0.10). 5 dose significantly improved total score, 7.5 (0, 18; 0.01) dimension, 4 8; 0.01), compared placebo. Changes 0.33; less 0.35; weakly related to times, but corresponded well patients' ratings dyspnea fatigue.(ABSTRACT TRUNCATED AT 250 WORDS)